AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9850348 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms twice daily)
Number of subjects: 23
Study 9850348 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 23
Study 8120720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 79
Study 8120720 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 79
Study 2531051 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide and fenoterol nebulizer solutions
Number of subjects: 0
Study 2531051 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol nebulizer solution
Number of subjects: 0
Study 788000 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxiptilin
Number of subjects: 62
Study 788000 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 62
Study 31311460 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with doubt
Number of subjects: 650
Study 31311460 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 650
Study 28008098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 pmol·kg−1·min−1 BNP
Number of subjects: 10
Study 28008098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26004151 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticosteroid (GS) treatment
Number of subjects: 48
Study 26004151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 48
Study 26004151 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 48
Study 23859438 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention
Number of subjects: 53
Study 23859438 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to program sections
Number of subjects: 53
Study 23859438 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 53
Study 21366172 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (300 mg)
Number of subjects: 40
Study 21366172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19273705 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide consolidation therapy for 12 months
Number of subjects: 269
Study 19273705 — intervention group
Group type: COMPARATOR
Intervention: Control group with indefinite prednisolone maintenance therapy
Number of subjects: 269
Study 17327603 — intervention group
Group type: EXPERIMENTAL
Intervention: Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols
Number of subjects: 844
Study 15546820 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (16 patients)
Number of subjects: 32
Study 15546820 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosulfan blue (16 patients)
Number of subjects: 32
Study 15546820 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 patients, no dyes used)
Number of subjects: 32
Study 11871585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered self-efficacy intervention given on five monthly occasions
Number of subjects: 56
Study 11871585 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 9924367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide (topical carbonic anhydrase inhibitor, three times daily, one eye)
Number of subjects: 33
Study 9924367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle treatment)
Number of subjects: 33
Study 8000692 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 14
Study 8000692 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 14
Study 30206918 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair skills training (n=13)
Number of subjects: 24
Study 30206918 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise sessions (n=11)
Number of subjects: 24
Study 26827067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered MIS® Seven implants (TI)
Number of subjects: 47
Study 26827067 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical Astra® Osseospeed implants (CI)
Number of subjects: 47
Study 24866311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment strategy
Number of subjects: 115
Study 24866311 — intervention group
Group type: COMPARATOR
Intervention: Advice on diet and exercise (Control)
Number of subjects: 115
Study 22960434 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (250 mg)
Number of subjects: 34
Study 22960434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 34
Study 20222840 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 120
Study 20222840 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day plus r-FSH (37.5 units/day)
Number of subjects: 120
Study 20222840 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol (4 g) plus folic acid (400 microg) daily
Number of subjects: 120
Study 20222840 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol plus folic acid plus r-FSH (37.5 units/day)
Number of subjects: 120
Study 18258384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant temozolomide (TMZ) at 50 mg/m² (Group A)
Number of subjects: 160
Study 18258384 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant temozolomide (TMZ) at 75 mg/m² (Group B)
Number of subjects: 160
Study 15920447 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 2 g amoxicillin 1 hour before every appointment (n=23)
Number of subjects: 39
Study 15920447 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n=24)
Number of subjects: 39
Study 12829663 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of single-agent paclitaxel administered every 28 days
Number of subjects: 277
Study 12829663 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of single-agent paclitaxel administered every 28 days
Number of subjects: 277
Study 12829663 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 277
Study 10390255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg/kg bid for 3 days, then 0.15 mg/kg bid for 3 days, followed by a tapering schedule to 0.1 mg/kg until 42 days)
Number of subjects: 118
Study 10390255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118
Study 10390255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 118
Study 9014716 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electroresection of the prostate (TURP)
Number of subjects: 46
Study 9014716 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electrovaporization (TUEP) using 240-300 W of cutting current
Number of subjects: 46
Study 2004805 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg/day)
Number of subjects: 14
Study 2004805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6833676 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine pretreatment followed by high doses of methacholine
Number of subjects: 6
Study 6833676 — intervention group
Group type: COMPARATOR
Intervention: Cromolyn sodium (40 mg) pretreatment
Number of subjects: 6
Study 31589864 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic laparoendoscopic single-site sacrocolpopexy
Number of subjects: 70
Study 31589864 — intervention group
Group type: COMPARATOR
Intervention: Multi-port robotic sacrocolpopexy
Number of subjects: 70
Study 29458915 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 63
Study 29458915 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 63
Study 26733462 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention group
Number of subjects: 103
Study 26733462 — intervention group
Group type: COMPARATOR
Intervention: Standard health care (control group)
Number of subjects: 103
Study 24966097 — intervention group
Group type: COMPARATOR
Intervention: Normal physiological saline (PS)
Number of subjects: 627
Study 24966097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 627
Study 24966097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of PS + N-acetylcysteine (NAC)
Number of subjects: 627
Study 24966097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of SB + NAC
Number of subjects: 627
Study 22306907 — intervention group
Group type: EXPERIMENTAL
Intervention: GC+CIK (gemcitabine and cisplatin plus autologous cytokine-induced killer cell transfusion)
Number of subjects: 60
Study 22306907 — intervention group
Group type: COMPARATOR
Intervention: GC (gemcitabine and cisplatin chemotherapy alone)
Number of subjects: 60
Study 22306907 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 60
Study 22306907 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 60
Study 20410684 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM-DM group (pantoprazole 40 mg b.i.d., bismuth citrate 400 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg b.i.d. for 14 days)
Number of subjects: 89
Study 20410684 — intervention group
Group type: COMPARATOR
Intervention: PCA-DM group (pantoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 14 days)
Number of subjects: 89
Study 20410684 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM-non-DM group (quadruple therapy for 14 days)
Number of subjects: 89
Study 20410684 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful eradication in DM patients
Number of subjects: 89
Study 20410684 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful eradication in DM patients
Number of subjects: 89
Study 18545194 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REX) with unloaded leg on an inertial resistance ergometer and albuterol (16 mg.d)
Number of subjects: 0
Study 18545194 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (REX) with unloaded leg on an inertial resistance ergometer and placebo (lactose)
Number of subjects: 0
Study 15503297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (10 microg/kg/day)
Number of subjects: 97
Study 15503297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day)
Number of subjects: 97
Study 15503297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (1,800 mg/m2/day on day 0‐4), carboplatin (400 mg/m2/day on day 0‐1), etoposide (100 mg/m2/day on day 0‐4) with rhG‐CSF (5 microg/kg/day) and IL‐6 (2.5‐5 microg/kg/day)
Number of subjects: 97
Study 12425706 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted behavioral training (n = 73)
Number of subjects: 222
Study 12425706 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training without biofeedback (verbal feedback based on vaginal palpation; n = 74)
Number of subjects: 222
Study 12425706 — intervention group
Group type: COMPARATOR
Intervention: Self-administered behavioral treatment using a self-help booklet (control condition; n = 75)
Number of subjects: 222
Study 12425706 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 222
Study 10512900 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipoprotein(a) levels in female cases
Number of subjects: 302
Study 10512900 — intervention group
Group type: COMPARATOR
Intervention: Plasma Lp(a) levels
Number of subjects: 302
Study 10512900 — intervention group
Group type: COMPARATOR
Intervention: C pneumoniae-specific IgG or IgA antibodies
Number of subjects: 302
Study 10512900 — intervention group
Group type: COMPARATOR
Intervention: Antibody titers
Number of subjects: 302
Study 10512900 — intervention group
Group type: COMPARATOR
Intervention: C pneumoniae IgG titer in combination with high Lp(a) level
Number of subjects: 302
Study 7540922 — intervention group
Group type: EXPERIMENTAL
Intervention: PDD subjects
Number of subjects: 20
Study 7540922 — intervention group
Group type: COMPARATOR
Intervention: N subjects
Number of subjects: 20
Study 1781524 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine plus fentanyl
Number of subjects: 30
Study 1781524 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine alone
Number of subjects: 30
Study 6171898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 12 mg per kg daily of 5‐FU for four consecutive days, then 6 mg per kg on alternate days to the point of toxicity or to a maximum of five doses, followed by 12 mg per kg weekly for one year
Number of subjects: 319
Study 6171898 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy
Number of subjects: 319
Study 30629465 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltrant (Icon)
Number of subjects: 21
Study 30629465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant (Helioseal Clear)
Number of subjects: 21
Study 30629465 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive (Adper Scotchbond Multi‐Purpose Plus)
Number of subjects: 21
Study 30629465 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 21
Study 30573125 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted rivaroxaban
Number of subjects: 127
Study 27388566 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent Graft (SG)
Number of subjects: 270
Study 27388566 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA)
Number of subjects: 270
Study 24857044 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/Erlotinib followed by Gemcitabine (CEG)
Number of subjects: 274
Study 24857044 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Erlotinib followed by Capecitabine (GEC)
Number of subjects: 274
Study 24857044 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (at any time during study treatment)
Number of subjects: 274
Study 22308054 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice root extract (2g aqueous extract per day for 2 months)
Number of subjects: 66
Study 22308054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22308054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 21336431 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat enriched in walnut paste (WM)
Number of subjects: 22
Study 21336431 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meat (LM)
Number of subjects: 22
Study 18724189 — intervention group
Group type: EXPERIMENTAL
Intervention: Eban HIV intervention condition
Number of subjects: 0
Study 18724189 — intervention group
Group type: COMPARATOR
Intervention: General Health Promotion condition
Number of subjects: 0
Study 15936560 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conservation therapy (BCT)
Number of subjects: 121
Study 12658913 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/day) or Olanzapine (10 mg/day)
Number of subjects: 17
Study 11111259 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental program (Choices)
Number of subjects: 168
Study 11111259 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 168
Study 8874658 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 500 micrograms bid
Number of subjects: 20
Study 8874658 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (P)
Number of subjects: 20
Study 8874658 — intervention group
Group type: COMPARATOR
Intervention: Comparison between BDP and placebo
Number of subjects: 20
Study 8253362 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent Cox regression model
Number of subjects: 237
Study 8253362 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-dependent Cox regression model with histological variables
Number of subjects: 237
Study 3020725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG) skin scarification
Number of subjects: 96
Study 3020725 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not receiving BCG)
Number of subjects: 96
Study 3020725 — intervention group
Group type: COMPARATOR
Intervention: Patients not in the study
Number of subjects: 96
Study 3020725 — intervention group
Group type: COMPARATOR
Intervention: T1N0 patients
Number of subjects: 96
Study 3020725 — intervention group
Group type: COMPARATOR
Intervention: T2N0 patients
Number of subjects: 96
Study 3020725 — intervention group
Group type: COMPARATOR
Intervention: All patients
Number of subjects: 96
Study 31499397 — intervention group
Group type: EXPERIMENTAL
Intervention: Active manual exploration training
Number of subjects: 50
Study 31499397 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational manual exploration training
Number of subjects: 50
Study 31499397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 50
Study 30231252 — intervention group
Group type: EXPERIMENTAL
Intervention: BNO 1045
Number of subjects: 659
Study 30231252 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin Trometamol (FT)
Number of subjects: 659
Study 26612385 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sleep (4.5 h)
Number of subjects: 0
Study 26612385 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (8.5 h)
Number of subjects: 0
Study 24050121 — intervention group
Group type: COMPARATOR
Intervention: Semi-vegetarians (n=37)
Number of subjects: 272
Study 22189827 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine A 0.05% eye drops (one drop twice daily)
Number of subjects: 62
Study 22189827 — intervention group
Group type: COMPARATOR
Intervention: preservative‐free hyaluronic acid artificial tears (one drop 5 times per day)
Number of subjects: 62
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus universal type in HFMD patients
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 in HFMD patients
Number of subjects: 154
Study 21055092 — intervention group
Group type: COMPARATOR
Intervention: Enterovirus universal type in suspected herpangina
Number of subjects: 154
Study 21055092 — intervention group
Group type: COMPARATOR
Intervention: EV71 in suspected herpangina
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 positive rate in severe HFMD
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 positive rate in mild HFMD
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison between mild and severe HFMD
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison between mild and severe HFMD
Number of subjects: 154
Study 21055092 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus load comparison between mild and severe HFMD
Number of subjects: 154
Study 17582281 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/d
Number of subjects: 304
Study 17582281 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg/d (after titration)
Number of subjects: 304
Study 17582281 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg/d
Number of subjects: 304
Study 15616082 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg/kg clonidine
Number of subjects: 48
Study 15616082 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48
Study 15616082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 48
Study 12067198 — intervention group
Group type: EXPERIMENTAL
Intervention: Random item placement format
Number of subjects: 0
Study 12067198 — intervention group
Group type: COMPARATOR
Intervention: Grouped item placement format
Number of subjects: 0
Study 10195533 — intervention group
Group type: COMPARATOR
Intervention: 0 mg meperidine
Number of subjects: 0
Study 10195533 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg meperidine
Number of subjects: 0
Study 10195533 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg meperidine
Number of subjects: 0
Study 10195533 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg meperidine
Number of subjects: 0
Study 10195533 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg meperidine
Number of subjects: 0
Study 10195533 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg meperidine
Number of subjects: 0
Study 7594664 — intervention group
Group type: EXPERIMENTAL
Intervention: PncOMPC vaccine (tetravalent pneumococcal conjugate vaccine)
Number of subjects: 93
Study 2263084 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide acetate (100 micrograms)
Number of subjects: 6
Study 2263084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6104131 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin given by mouth in therapeutic doses
Number of subjects: 0
Study 6104131 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 0
Study 6104131 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy without specific drug treatment
Number of subjects: 0
Study 31025924 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of subcutaneous NTK
Number of subjects: 89
Study 31025924 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of subcutaneous NTK
Number of subjects: 89
Study 31025924 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of subcutaneous NTK
Number of subjects: 89
Study 31025924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 31454263 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 1641
Study 31454263 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1641
Study 27989775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 28
Study 27989775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28